The Best Pharmaceuticals for Children Act (BPCA) directs the Secretary of HHS, acting through the Director of the National Institutes of Health (NIH) and in consultation with the Commissioner of the Food and Drug Administration (FDA) and experts in pediatric research to develop and prioritize a list of drugs for which pediatric studies are needed. The NIH Director delegated responsibility for implementing the BPCA to the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). This IAA is in support of the BPCA.
